Abstract: Formulations with enhanced SN-38 solubility and oral absorption. In one embodiment, a formulation or a pharmaceutical composition comprises (a) 7-Ethyl-10-hydroxy-camptothecin (SN-38); and (b) a mixture of pharmaceutically acceptable excipients comprising (i) N-Methylpyrrolidone; and (ii) Vitamin E TPGS or a copolymer, the copolymer being 50/50 poly(lactic-co-glycolic acid), or 75/25 poly(lactic-co-glycolic acid) (PLGA); with the provision that if the VitE TPGS is present, the mixture of the excipients further comprises a polymer selected from the group consisting of Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, VP/VAc copolymer 60/40, poloxamer 407, and Lauroyl Macrogol-32 glycerides; wherein the pharmaceutical composition contains no water, is in a liquid or a gel form, and the SN-38 is dissolved in the mixture of the excipients without precipitation.

Abstract: Compositions for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis in a subject in need thereof are disclosed. The composition comprises a therapeutically effective amount of an anthraquinone derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle. In one embodiment, the composition comprises diacerein. Also disclosed is a first composition comprising an anthraquinone derivative selected from the group consisting of diacerein, aloe-emodin, emodin, and rhein, and a first pharmaceutically acceptable vehicle; and a second composition comprising mesalazine, and a second pharmaceutically acceptable vehicle, in combination for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis.

Abstract: Compositions for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis in a subject in need thereof are disclosed. The composition comprises a therapeutically effective amount of an anthraquinone derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle. In one embodiment, the composition comprises diacerein. Also disclosed is a first composition comprising an anthraquinone derivative selected from the group consisting of diacerein, aloe-emodin, emodin, and rhein, and a first pharmaceutically acceptable vehicle; and a second composition comprising mesalazine, and a second pharmaceutically acceptable vehicle, in combination for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis.

Abstract: Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases. In another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.

Abstract: Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases, in another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.

Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.

Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.

Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.

Abstract: This invention relates to compositions containing a compound of formula (I) shown below: Each variable is defined in the specification. Also disclosed are methods of using these compositions to treat acne, psoriasis, and infective skin ulcer.

Abstract: This invention relates to compositions containing a compound of formula (I) shown below: Each variable is defined in the specification. Also disclosed are methods of using these compositions to treat acne, psoriasis, and infective skin ulcer.

Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.

Abstract: The invention relates to a method of detecting a differentially expressed gene in a first sample of nucleic acids representing a first population of RNA transcripts and a second sample of nucleic acids representing a second population of RNA transcripts. The nucleic acids in the samples are labled with a member of specific binding pair, and the labeled nucleic acids in each sample are then hybridized to an excess of copies of a gene-specific sequence. The hybridized nucleic acids in each sample are further labeled by binding a second member of the specific binding pair to the first member, in which the second member has an activity to convert a chromogenic substrate into a chromogen. As a result of contacting the second member with the chromogenic substrate, the chromogenic substrate is converted into the chromogen. A difference in the amounts of chromogen produced from assaying the two samples indicate that the gene-specific sequence is differentially expressed in the samples.